SCHEMBL5120009

SCHEMBL5120009

CCOC(=O)c1ccc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 2/20 0.62
SLC10A2 Q12908 1/20 0.62
SLC10A1 Q14973 1/20 0.62
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 4/20 0.57
LMNA P02545 4/20 0.57
GPR27 Q9NS67 3/20 0.54
MAPT P10636 4/20 0.54
NHERF1 O14745 1/20 0.54
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
HPGD P15428 2/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CRHBP P24387 1/20 0.53
CYP2C19 P33261 1/20 0.53
CRHR2 Q13324 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126247 0.90 KDM4E (0.65) SLC10A6SLC10A2SLC10A1KDM4EALDH1A1
SCHEMBL7209259 0.90 LMNA (0.67) SLC10A6SLC10A2SLC10A1KDM4EALDH1A1
SCHEMBL5118820 0.89 LMNA (0.58) SLC10A6SLC10A2SLC10A1KDM4EALDH1A1
SCHEMBL5118364 0.88 SLC10A6 (0.55) SLC10A6SLC10A2SLC10A1KDM4EALDH1A1
SCHEMBL6754585 0.86 SLC10A6 (0.81) SLC10A6SLC10A2SLC10A1KDM4EALDH1A1
SCHEMBL492283 0.85 SLC10A6 (0.69) SLC10A6SLC10A2SLC10A1KDM4EGPR27
SCHEMBL5126186 0.85 SLC10A6 (0.69) SLC10A6SLC10A2SLC10A1KDM4ELMNA
SCHEMBL6862400 0.84 SLC10A6 (0.71) SLC10A6SLC10A2SLC10A1KDM4EGPR27
SCHEMBL492298 0.84 SLC10A6 (0.59) SLC10A6SLC10A2SLC10A1KDM4ELMNA
SCHEMBL6760783 0.84 SLC10A6 (0.74) SLC10A6SLC10A2SLC10A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 SLC10A6 2987/4885SLC10A2 1391/4885SLC10A1 1242/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 SLC10A6 3299/4885SLC10A2 1534/4885SLC10A1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.